Nader Pourhassan, CytoDyn CEO (Photo by Jeff Kravitz/FilmMagic for CytoDyn’s Pro)

Cy­to­Dyn faces DOJ, SEC sub­poe­nas af­ter pro­mot­ing failed Covid-19 drug

The lit­tle, PR-hap­py drug com­pa­ny pub­licly called out by the FDA is now get­ting at­ten­tion from both the SEC and the De­part­ment of Jus­tice.

Cy­to­Dyn, a one-time pen­ny stock that has gained both mon­ey and no­to­ri­ety for ag­gres­sive­ly push­ing an old HIV drug as a treat­ment for Covid-19, dis­closed in a reg­u­la­to­ry fil­ing Fri­day the SEC and DOJ have sep­a­rate­ly sub­poe­naed the com­pa­ny and “cer­tain of its ex­ec­u­tives” as part of in­ves­ti­ga­tions in­to the com­pa­ny’s pro­mo­tion and mar­ket­ing prac­tices.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.